Skip to main content

Table 4 Familial relative risk for breast cancer by marker status of index case tumour and age of relative *

From: Familial relative risks for breast cancer by pathological subtype: a population-based cohort study

Phenotype

Age of relative (years)*

OBS

EXP

FRR

95%CI

PR-positive

     
 

<50

60

29.46

2.04

1.52 to 2.55

 

50 to 84

187

102.77

1.82

1.55 to 2.10

 

0 to 84

247

132.23

1.87

1.63 to 2.11

PR-negative

     
 

<50

46

13.39

3.44

2.37 to 4.50

 

50 to 84

65

46.00

1.41

1.06 to 1.76

 

0 to 84

111

59.39

1.87

1.55 to 2.24

HER2-positive

     
 

<50

11

4.17

2.64

1.08 to 4.20

 

50 to 84

25

13.70

1.83

1.08 to 2.57

 

0 to 84

36

17.86

2.02

1.34 to 2.69

HER2-negative

     
 

<50

65

28.50

2.28

1.73 to 2.86

 

50 to 84

154

100.77

1.53

1.28 to 1.77

 

0 to 84

219

129.27

1.69

1.46 to 1.92

ER+PR+

     
 

<50

55

27.20

2.02

1.49 to 2.56

 

50 to 84

173

95.89

1.80

1.52 to 2.08

 

0 to 84

228

123.10

1.85

1.60 to 2.10

ER-PR+

     
 

<50

5

1.91

2.62

0.33 to 4.91

 

50 to 84

12

5.74

2.09

0.84 to 3.35

 

0 to 84

17

7.64

2.22

1.16 to 3.32

ER+PR-

     
 

<50

15

4.13

3.63

1.85 to 5.41

 

50 to 84

24

16.31

1.47

0.88 to 2.06

 

0 to 84

39

20.44

1.91

1.31 to 2.51

ER or PR+ (luminal)

     
 

<50

140

68.04

2.06

1.71 to 2.40

 

50 to 84

437

247.27

1.77

1.61 to 1.94

 

0 to 84

577

315.30

1.83

1.68 to 1.98

ER or PR+ HER2+ (luminal HER2+)

     
 

<50

6

2.68

2.24

0.48 to 4.00

 

50 to 84

16

8.35

1.92

0.94 to 2.90

 

0 to 84

22

11.03

2.00

1.15 to 2.84

ER or PR+ HER2- (luminal HER2-)

     
 

<50

53

23.49

2.26

1.65 to 2.87

 

50 to 84

136

85.67

1.59

1.32 to 1.86

 

0 to 84

189

109.15

1.73

1.48 to 2.00

ER-PR- (non-luminal)

     
 

<50

31

9.17

3.38

2.05 to 4.72

 

50 to 84

41

29.10

1.41

0.97 to 1.85

 

0 to 84

72

38.26

1.88

1.41 to 2.35

ER-PR-HER2+ (non-luminal HER2+)

     
 

<50

4

1.25

3.20

1.20 to 8.85

 

50 to 84

6

4.52

1.33

0.35 to 2.29

 

0 to 84

10

5.77

1.73

0.61 to 2.86

ER-PR-HER2- (TN)

     
 

<50

9

4.12

2.18

0.77 to 3.59

 

50 to 84

15

12.55

1.20

0.60 to 1.79

 

0 to 84

24

16.67

1.44

0.85 to 2.03

  1. CI: confidence interval; ER: estrogen receptor; EXP: expected; FRR: familial relative risk; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; OBS: observed; TN: triple negative.
  2. * <50: relatives were followed up from birth up until censoring or age 50, whichever occurred first, 50-84: from age 50 to censoring, 0-85: from birth to censoring
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us